> IDIX – I find it surprising that the Co has not issued a PR concerning the DDW presentations.<
I just got off the phone with IR. The answer: IDIX will PR and prominently highlight the final (48-week) data of the phase-3b trial of Telbivudine vs Hepsera at AASLD in October, which is the biggest hepatitis conference on the circuit; they didn’t think the interim (24-week) data warranted a PR. Odd, but that’s what they said.
>…the CEO bought shares at $9.xx this month, which now trade below his entry price<
I don’t think JP Sommadossi is especially worried about that. Unless there is some kind of problem with the Telbivudine reviews at the FDA and EMEA, JP figures to do quite well on the recent purchase as well as his overall holding of 2.2M shares. Regards, Dew
Market Data 
Markets 
AI
